10 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the Navipharm Co., Ltd. portfolio ends in Jun 2031, and more of its terms end in 2038 (3) than in any other year. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2031
Next term end
7
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2037 · High confidence
Also notable
Ends Apr 2038 · High confidence
Also notable
Ends Jan 2039 · High confidence
Also notable
Ends Sep 2040 · High confidence
Also notable
Ends Apr 2036 · High confidence
Also notable
Ends Jun 2031 · High confidence
Also notable
Ends Feb 2043 · High confidence
Novel Lactobacillus Having Various Functions, and Use Thereof
US 11,202,811
Granted 2021. Computed term ends 2037.
Novel Lactic Acid Bacteria and Use Thereof
US 11,554,146
Granted 2023. Computed term ends 2038.
Novel Lactic Acid Bacteria and Use Thereof
US 11,324,786
Granted 2022. Computed term ends 2039.
Method of Treatment with Lactic Acid Bacteria
US 11,660,321
Granted 2023. Computed term ends 2040.
Rivastigmine-Containing Sustained-Release Pharmaceutical Composition
US 10,835,497
Granted 2020. Computed term ends 2036.
Composition for Preventing or Treating Osteoporosis, and Manufacturing Method Therefor
US 9,044,401
Renewed at every maintenance window since the 2015 grant; no more fees are due before its term ends in 2031.
Novel Lactic Acid Bacteria and Use Thereof
US 12,447,184
Granted 2025. Too new for citation comparison; protection runs to 2043.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 23, 2027The maintenance fee for Novel Lactic Acid Bacteria and Use Thereof (US 11,963,988) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 24, 2026
What they patent
The largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Method of Treatment with Lactic Acid Bacteria | 2 in force | to Sep 2040 |
| Novel Lactic Acid Bacteria and Use Thereof (2020) | 2 in force | to Jan 2039 |
| Novel Lactic Acid Bacteria and Use Thereof (2020) | 2 in force | to Apr 2038 |
| Novel Lactic Acid Bacteria and Use Thereof (2019) | 1 in force | to Feb 2043 |
| Novel Lactobacillus Having Various Functions, and Use Thereof | 1 in force | to Mar 2037 |
| Rivastigmine-Containing Sustained-Release Pharmaceutical Composition | 1 in force | to Apr 2036 |
| Composition for Preventing or Treating Osteoporosis, and Manufacturing Method Therefor | 1 in force | to Jun 2031 |
Patents held now
Soonest term end first.
Showing 1 to 10 of 10
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,044,401 | Composition for Preventing or Treating Osteoporosis, and Manufacturing Method Therefor held by Navipharm Co., Ltd. and Dream Pharma Corporation In force · High confidence | In force | High confidence | |
| US 10,835,497 | Rivastigmine-Containing Sustained-Release Pharmaceutical Composition In force · High confidence | In force | High confidence | |
| US 11,202,811 | Novel Lactobacillus Having Various Functions, and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,554,146 | Novel Lactic Acid Bacteria and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,036,253 | Novel Lactic Acid Bacteria and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,963,988 | Novel Lactic Acid Bacteria and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,324,786 | Novel Lactic Acid Bacteria and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,778,991 | Method of Treatment with Lactic Acid Bacteria In force · High confidence | In force | High confidence | |
| US 11,660,321 | Method of Treatment with Lactic Acid Bacteria In force · High confidence | In force | High confidence | |
| US 12,447,184 | Novel Lactic Acid Bacteria and Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 2 patents in force now held by others · 1 application pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.